News | April 01, 2011

Portable Brain Imaging System can Rapidly Detect Stroke


April 1, 2011 – Jan Medical announced that clinical data related to its portable brain imaging system were disclosed at the Society of Interventional Radiology Annual Meeting. The data demonstrated a breakthrough in detecting strokes.

The system is designed for the diagnosis of traumatic brain injury, including concussions.
Diagnosis utilizing the device takes minutes. It emits no energy into the brain and is therefore positioned as a “Non-Significant Risk” in clinical trial protocols. Continuous monitoring options include hours, days or weeks until the condition is resolved or requires intervention. All other brain imaging alternatives, such as CT and MRI, are snapshots.

Kieran J. Murphy, M.D., vice chair and deputy chief of medical imaging and director of medical imaging research at the University of Toronto presented the data.

“Our study validates that the Jan Medical system represents a new paradigm for detecting, diagnosing and monitoring of stroke,” said Murphy. “The small size, portability and rapidity of imaging will allow diagnosis of stroke victims in minutes, which in turn will allow for stroke triage outside of a hospital setting, thus further reducing the time to initial treatment—which should dramatically improve patient outcomes.”

“Stroke is the third-leading cause of death in the U.S. and the leading cause of disability,” added Paul Lovoi, Ph.D., CEO of Jan Medical. “While some 1.5 million patients present annually with what appear to be stroke symptoms, half of them have actually not had a stroke. We believe that our system can have an enormously favorable impact by empowering healthcare providers to make a reliable assessment of stroke in just minutes. Patient outcomes will then be improved because healthcare providers will have the correct and timely information they need to treat their patients faster, at lower cost and less risk.”

The Jan Medical System is an investigational device in the United States.

For more information: www.janmedical.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now